Investors

Investors

Company Information

 

Agenus is an immuno-oncology company focused on the discovery and development of revolutionary new treatments that engage the body’s immune system to benefit patients suffering from cancer. By combining multiple powerful platforms, Agenus has established a highly integrated approach for the discovery, development and manufacture of monoclonal and multi-specific antibodies that modulate targets of interest, as well as allogeneic cell therapies through its subsidiary MiNK therapeutics. In addition, the Company’s cancer vaccine program includes proprietary individualized and off-the-shelf vaccines uniquely designed for each patient. Agenus’ broad portfolio of novel checkpoint and other immuno-modulatory antibodies, cell therapies, vaccines and adjuvants, work in combination to provide the opportunity to create best-in-class therapeutic regimens. The Company has formed collaborations with BMS, Gilead, Merck and Incyte to discover and develop multiple checkpoint antibodies.

Press Releases
May 25, 2022
LEXINGTON, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced that its Annual Shareholders Meeting will begin at 3:30 p.m.
May 25, 2022
LEXINGTON, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced that Dr. Garo Armen, Chairman and CEO of Agenus and Dr.

btn News

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

btn Stock

SEC Filings

Form Description Filing date View
10-Q

Quarterly report which provides a continuing view of a company's financial position

View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
8-K

Report of unscheduled material events or corporate event

View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
DEF 14A

Official notification to shareholders of matters to be brought to a vote ("Proxy")

View HTML
SC 13G

A statement of beneficial ownership of common stock by certain persons

View HTML

Data provided by Kaleidoscope.

btn SEC